Boston Trust Walden Corp Increases Stock Position in Bio-Rad Laboratories, Inc. $BIO

Boston Trust Walden Corp raised its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 93,495 shares of the medical research company’s stock after buying an additional 3,657 shares during the period. Boston Trust Walden Corp’s holdings in Bio-Rad Laboratories were worth $26,062,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of BIO. First Eagle Investment Management LLC grew its position in shares of Bio-Rad Laboratories by 2.0% during the 4th quarter. First Eagle Investment Management LLC now owns 2,570,473 shares of the medical research company’s stock valued at $778,828,000 after acquiring an additional 50,154 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Bio-Rad Laboratories by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,077,072 shares of the medical research company’s stock valued at $326,344,000 after buying an additional 14,134 shares in the last quarter. Earnest Partners LLC grew its stake in Bio-Rad Laboratories by 0.6% in the 3rd quarter. Earnest Partners LLC now owns 609,284 shares of the medical research company’s stock valued at $170,837,000 after acquiring an additional 3,398 shares during the period. Capital Research Global Investors grew its stake in Bio-Rad Laboratories by 18.2% in the 4th quarter. Capital Research Global Investors now owns 494,472 shares of the medical research company’s stock valued at $149,820,000 after acquiring an additional 76,117 shares during the period. Finally, Bank of America Corp DE increased its holdings in Bio-Rad Laboratories by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 459,887 shares of the medical research company’s stock worth $128,948,000 after acquiring an additional 7,754 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Ratings Changes

BIO has been the subject of several research analyst reports. Royal Bank Of Canada started coverage on shares of Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price target for the company. Weiss Ratings downgraded Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $303.33.

Bio-Rad Laboratories Price Performance

Shares of BIO stock opened at $296.78 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37. The company has a market capitalization of $7.94 billion, a PE ratio of 48.89 and a beta of 1.08. The firm’s 50-day moving average is $284.09 and its two-hundred day moving average is $288.04. Bio-Rad Laboratories, Inc. has a 12 month low of $236.73 and a 12 month high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The firm had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The firm’s quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.54 EPS. Analysts predict that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.